Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis—Sionna Therapeutics (SION) priced its upsized initial public offering of ...

Terns Pharmaceuticals, Inc., a biopharmaceutical company with a market capitalization of $397 million, disclosed the departure of their Chief Financial Officer (CFO), Mark Vignola, Ph.D., effective ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

The successful financings come amid a more than two-year stretch when the sector has struggled to attract fresh capital with ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

BioPharma announced that its licensee Celly Nutrition Corporation, the company behind unbuzzd announced that it has engaged a leading New York ...

On a per-share basis, the Princeton, New Jersey-based company said it had net income of 4 cents. Earnings, adjusted for non-recurring costs, came to $1.67 per share. The results surpassed Wall Street ...

Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at ...

Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher.

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.